Friedegund Meier

Abstract Leptomeningeal metastatic disease (LMD) of solid tumors represents a cancer stage with high unmet therapeutic need. Here we report results from the dose escalation part of a multicenter phase 1 trial investigating intraventricular nivolumab, now continuing in the expansion part. Eligible participants had LMD from tumors with an approval for intraveneous PD1/PDL1 therapy or high tumor mutational burden.

BACKGROUND: Measurement of health-related quality of life (HRQoL) in patients with melanoma under immune checkpoint inhibitor therapy (ICI) under routine conditions and in survivorship is insufficient due to the absence of data and therapy-specific instruments in clinical trials. This pilot study aimed to collect and compare data on symptom burden and HRQoL in patients during and after ICI therapy.

BACKGROUND: The incidence of severe immune-related hepatitis (irHepatitis) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 under combination therapy with ipilimumab and nivolumab ranges from 15% to 20%. Current clinical guidelines recommend initiating treatment with systemic corticosteroids, followed by second-line immunosuppressants such as mycophenolate mofetil.